TREM2 and metabolic dysfunction-associated steatotic liver disease: More recently, different laboratories have described the emergence, during NAFLD progression and/or in condition of altered lipid metabolism, of a peculiar macrophage phenotype characterized by the expression of Triggering Receptor Expressed on Myeloid cells-2 or TREM2, CD9 and CD68 (18–21), sometimes referred to as NASH-associated macrophages (NAMs) or hepatic lipid-associated macrophages (hepatic LAMs).